A novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: Systemic acitretin and intralesional fluorouracil

JAMA Dermatology

Volumn 149, Issue 3, 2013, Pages 279-281

  LaPresto, Lindsay ^b   Cranmer, Lee ^a,b   Morrison, Lynne ^a   Erickson, Christof P ^c   Curiel Lewandrowski, Clara ^a,b,d  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c Dermpath Diagnostics   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; ETRETIN; FLUOROURACIL; VEMURAFENIB;

ADVERSE OUTCOME; AGED; ARTICLE; CANCER PREVENTION; CASE REPORT; CLINICAL EVALUATION; HUMAN; HUMAN TISSUE; KERATOACANTHOMA; MALE; MELANOMA; METASTASIS; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SKIN BIOPSY; SKIN EXFOLIATION; SKIN SURGERY; SQUAMOUS CELL CARCINOMA;

ACITRETIN; AGED; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; FLUOROURACIL; HUMANS; INDOLES; INJECTIONS, INTRALESIONAL; KERATOACANTHOMA; KERATOLYTIC AGENTS; MALE; MELANOMA; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84875397058     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.2583     Document Type: Article

References (6)

1. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-714.
2. Zelboraf [package insert]. South San Francisco, CA: Genentech, Inc; 2012.
3. Good LM, Miller MD, High WA. Intralesional agents in the management of cutaneous malignancy: a review. J Am Acad Dermatol. 2011;64(2):413-422.
4. Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol. 1995;13(8):1933-1938.
5. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207-215.
6. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-1703.